Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (101-110 of 208) with videos related to

Pageof 21
Sort By:
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Medrxiv : the Preprint Server for Health Sciences|July 29, 2024
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitorsXuefeng Wang, Tingyi Li, Islam Eljilany, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 studyShailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Signal Transduction and Targeted Therapy|May 1, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancerAnmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Cancers|October 28, 2023
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint InhibitorsIslam Eljilany, Payman Ghasemi Saghand, James Chen, et al.
Melanoma Research|October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600ESigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Journal of Translational Medicine|June 3, 2021
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, et al.
Pageof 21

Showing results (101-110 of 208) with videos related to

Sort By:
Pageof 21
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Medrxiv : the Preprint Server for Health Sciences|July 29, 2024
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitorsXuefeng Wang, Tingyi Li, Islam Eljilany, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 studyShailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Signal Transduction and Targeted Therapy|May 1, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancerAnmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Cancers|October 28, 2023
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint InhibitorsIslam Eljilany, Payman Ghasemi Saghand, James Chen, et al.
Melanoma Research|October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600ESigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Journal of Translational Medicine|June 3, 2021
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, et al.
Pageof 21